Skip to main content

Table 2 Treatment details and prognoses of first-line chemotherapy

From: Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

  Single-agent (N = 20) Platinum doublet (N = 11)
Regimen
 Gemcitabine 8 (40.0%) 0
 Vinorelbine 6 (30.0%) 0
 Docetaxel 5 (25.0%) 0
 Pemetrexed 1 (5.0%) 0
 Carboplatin + weekly paclitaxel 0 9 (81.8%)
 Carboplatin + gemcitabine 0 1 (9.1%)
 Carboplatin + S-1 0 1 (9.1%)
Response rate (%) 0 45.4%
Disease control rate (%) 55.0% 54.5%
Progression free survival (month) 2.87 [0.60–7.27] 5.43 [1.58–8.07]
Number of treatment cycles 2.00 [1.00–2.25] 3.00 [1.00–4.00]
Early termination (only 1 cycle) (%) 7 (35.0%) 4 (36.4%)
Cause of cessation
 Adverse event 11 (55.0%) 4 (36.4%)
 Deterioration of physical condition 5 (25.0%) 0
 Completion of 4–6 cycles 0 5 (45.5%)
 Progressive disease 3 (15.0%) 1 (9.1%)
 Patient’s request 1 (5.0%) 1 (9.1%)
  1. Categorical data are presented as numbers (percentages) whereas continuous data are presented as medians (interquartile ranges)